(COR) Cencora - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03073E1055

COR: Pharmaceuticals, Vaccines, Healthcare, Equipment, Supplies, Software

Cencora, Inc. (NYSE: COR) operates as a global healthcare solutions provider, specializing in the sourcing and distribution of pharmaceutical products. The company serves a diverse range of customers, including acute care hospitals, retail pharmacies, and biotechnology manufacturers. Its U.S. Healthcare Solutions segment offers a comprehensive suite of services, including pharmaceutical distribution, pharmacy management, supply chain software, and clinical trial support. The segment also provides specialty products, such as injectable pharmaceuticals and vaccines, to healthcare providers. Additionally, Cencora serves the animal health market with products like vaccines and parasiticides, and offers data analytics and consulting services to pharmaceutical manufacturers.

The company’s International Healthcare Solutions segment focuses on global pharmaceutical wholesale and commercialization services. It distributes healthcare products to international markets, including pharmacies, hospitals, and health centers. The segment also provides specialty logistics services for the biopharmaceutical industry. Cencora, formerly known as AmerisourceBergen Corporation, has a long history dating back to 1871. Headquartered in Conshohocken, Pennsylvania, the company rebranded as Cencora, Inc. in August 2023, reflecting its strategic evolution in the healthcare sector.

3-Month Forecast: Based on and , Cencora, Inc. (NYSE: COR) is expected to maintain upward momentum in the near term. The stock is trading above its 20-day and 50-day moving averages, with the SMA20 at $277.67 and SMA50 at $262.11. The average true range (ATR) of $6.72 suggests moderate volatility. With a forward P/E of 18.55, the stock is positioned for potential earnings growth. However, the high current P/E of 40.33 and P/B of 243.09 indicate elevated valuations. Investors should monitor the company’s ability to meet earnings expectations and sustain its revenue growth trajectory.

Additional Sources for COR Stock

COR Stock Overview

Market Cap in USD 56,587m
Sector Healthcare
Industry Medical Distribution
GiC Sub-Industry Health Care Distributors
IPO / Inception 1995-04-04

COR Stock Ratings

Growth Rating 90.8
Fundamental 59.1
Dividend Rating 53.0
Rel. Strength 33.2
Analysts 4.06/5
Fair Price Momentum 331.94 USD
Fair Price DCF 331.97 USD

COR Dividends

Dividend Yield 12m 0.62%
Yield on Cost 5y 1.89%
Annual Growth 5y 4.12%
Payout Consistency 99.6%

COR Growth Ratios

Growth Correlation 3m 96.6%
Growth Correlation 12m 79.5%
Growth Correlation 5y 98.3%
CAGR 5y 27.21%
CAGR/Max DD 5y 1.53
Sharpe Ratio 12m 0.67
Alpha 22.96
Beta 0.093
Volatility 21.51%
Current Volume 4122.8k
Average Volume 20d 1563.4k
What is the price of COR stocks?
As of May 09, 2025, the stock is trading at USD 283.77 with a total of 4,122,766 shares traded.
Over the past week, the price has changed by -2.29%, over one month by +3.29%, over three months by +15.44% and over the past year by +27.76%.
Is Cencora a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Cencora (NYSE:COR) is currently (May 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 59.11 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of COR as of May 2025 is 331.94. This means that COR is currently undervalued and has a potential upside of +16.98% (Margin of Safety).
Is COR a buy, sell or hold?
Cencora has received a consensus analysts rating of 4.06. Therefor, it is recommend to buy COR.
  • Strong Buy: 9
  • Buy: 1
  • Hold: 6
  • Sell: 1
  • Strong Sell: 0
What are the forecast for COR stock price target?
According to ValueRays Forecast Model, COR Cencora will be worth about 358.5 in May 2026. The stock is currently trading at 283.77. This means that the stock has a potential upside of +26.33%.
Issuer Forecast Upside
Wallstreet Target Price 297.5 4.8%
Analysts Target Price 295 4%
ValueRay Target Price 358.5 26.3%